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Monitorowanie chorych w ostrym okresie udaru mózgu. Zalecenia europejskie
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Department of Neurology, Ernst Moritz Arndt University, Greifswald
Abstract ___________________________________________________________________________
Acute stroke is one of the leading causes of morbidity and mortality worldwide. At the same time stroke has increasingly
been recognised as a medical emergency like myocardial infarction or severe trauma. Acute care of stroke patients in
specialised stroke units has been proven to be effective in acute ischaemic stroke. Accordingly, several neurological
societies have established guidelines for the management of acute stroke. A comprehensive set of recommendations,
together with an overview of established and widely used therapeutic strategies, has been published by the European Stroke
Initiative (EUSI). While revascularisation therapies such as IV and IA thrombolysis emerged as the only specific treatments
in acute stroke to have been demonstrated as being effective in multicentre randomised controlled trials, the general
supportive care and treatment of acute complications are of equal importance, even if these procedures have not been
investigated in randomised controlled trials. The present article aims to review the state-of-the-art general supportive care
which is usually provided on an acute care stroke unit.
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Streszczenie ________________________________________________________________________
Udar mózgu jest drugą lub trzecią pod względem częstości przyczyną zgonów na świecie oraz wiodącą przyczyną trwałego
inwalidztwa, szczególnie w krajach wysokorozwiniętych.
We wstępie pracy, dotyczącym ogólnych aspektów rozpoznawania udaru, autor przedstawił aktualne wytyczne postępowa-
nia w udarze mózgu, przede wszystkim na podstawie standardów opracowanych przez European Stroke Initiative (EUSI),
uzupełniając je o przegląd licznych doniesień z ostatnich lat.
Autor zaprezentował współczesny stan wiedzy na temat monitorowania stanu chorego w ostrym okresie udaru mózgu,
z uwzględnieniem aspektów praktycznych, między innymi wpływu poszczególnych parametrów na rokowanie i śmiertelność
oraz warunków funkcjonowania oddziału udarowego. Podstawowe zadania terapeutyczne w ostrej fazie udaru to: stabiliza-
cja ogólnego stanu chorego; ukierunkowane leczenie, na które składają się ewentualna rewaskularyzacja i neuroprotekcja;
profilaktyka i leczenie powikłań, takich jak: wtórne ukrwotocznienie udaru, obrzęk mózgu, napady padaczkowe, infekcje,
odleżyny, zakrzepowe zapalenie żył głębokich powikłane zatorowością płucną; wczesna rehabilitacja. W dalszej części pracy
omówiono techniki diagnostyczne przydatne w ostrej fazie udaru mózgu, a następnie szczegółowo przedstawiono zasady
monitorowania podstawowych funkcji życiowych, objawów neurologicznych ze szczególnym uwzględnieniem stanu świa-
domości, układu oddechowego, równowagi wodno-elektrolitowej, ciśnienia śródczaszkowego, funkcji układu krążenia, ciś-
nienia tętniczego, metabolizmu glukozy oraz termoregulacji.
Słowa kluczowe: udar mózgu, monitorowanie
Introduction
From a worldwide perspective, acute stroke is
one of the leading causes of morbidity and mortali-
ty. Particularly in industrialised countries stroke
ranks as either the second or the third most common
cause of death and as the leading cause of long-term
disability. With respect to long-term disability, stroke
also carries an enormous economic burden [1, 2].
Acute care of stroke patients in specialised
stroke units and has been proven effective in acu-
te ischaemic stroke [3]. A recent meta-analysis re-
vealed an 18% reduction in relative risk of morta-
lity, the number needed to treat (NNT) being 33, and
a 6% increase in independent survivors (NNT 16),
when patients were treated in a stroke unit as com-
pared to being admitted to a general medical ward
[3]. Accordingly, several neurological societies
have established guidelines for the management of
acute stroke [4–6]. A comprehensive set of recom-
mendations, together with an overview of establi-
shed and widely used therapeutic strategies, has
been published by the European Stroke Initiative
(EUSI) [7]. These recommendations can also be
assessed at the EUSI webpage at http://www.
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eusi-stroke.com. While revascularisation therapies
such as IV and IA thrombolysis emerged as the only
specific treatments in acute stroke to have been
demonstrated as being effective in multicentre ran-
domised controlled trials [8–10], general supporti-
ve care and treatment of acute complications are
of equal importance, even if these procedures have
not been investigated in randomised controlled
trials. The present article aims to review the state-
-of-the-art general supportive care which is usual-
ly provided on an acute care stroke unit.
Although stroke has increasingly been recogni-
sed as a medical emergency like myocardial infarc-
tion or serious trauma, the majority of stroke pa-
tients still do not reach hospital soon enough to
receive adequate therapy [11]. Several factors may
contribute to the delay between the onset of symp-
toms and arrival at a hospital [12]. A lack of awa-
reness by the victims or their relatives of the symp-
toms of stroke and resort to consultation with the
primary care physician instead of immediately cal-
ling 112 to activate the emergency medical system
(EMS) are obviously the most import issues which
need to be addressed in public education campa-
igns to improve stroke management during the pre-
-hospital phase [13–15]. Furthermore, it has to be
ensured that primary care physicians arrange prio-
rity transport and notify the receiving hospital for
all patients with stroke symptoms or stroke war-
ning signs or, if air transport is available, activate
helicopter transportation promptly if there is a long
distance to be travelled to the nearest in hospital
providing organised acute stroke care [16–20].
Given the narrow therapeutic windows for re-
vascularisation treatment of acute ischaemic stroke,
timely evaluation and diagnosis are of the utmost
importance [21]. Thus the in-hospital management
of acute stroke patients should follow written gu-
idelines and effective well co-ordinated pathways
[22]. A multidisciplinary approach to patient ma-
nagement is usually guaranteed by specialised stro-
ke units. In Europe different categories of stroke
unit exist, including acute stroke units, rehabilita-
tion stroke units and comprehensive stroke units,
which provide both acute stroke management and
stroke rehabilitation [23–27]. All categories of stro-
ke unit are defined as hospital units with dedica-
ted beds for stroke patients and a specialised team
consisting of stroke physicians, trained nurses and
rehabilitation staff, including physiotherapists,
occupational therapists, speech therapists and so-
cial workers, who are all trained in stroke rehabi-
litation or familiar with the problems of stroke pa-
tients. Stroke units providing acute stroke care,
such as those based on the German stroke unit
model [24], also make immediate imaging (CT or
MRI) and experience in revascularisation therapy
a requirement and both are available on a 24-
-hours-per-day, 7-days-per-week basis, together
with written guidelines and pathways for diagno-
stic procedures, acute treatment, monitoring to
prevent complications and for secondary preven-
tion, interventional neuroradiology, neurosurgery,
cardiology and vascular surgery, an immediate start
to mobilisation with prompt access to early reha-
bilitation, and continuing staff education [24].
Emergency treatment in the acute phase of
stroke targets the following goals: 1) stabilisation
of the general condition; 2) stroke-specific thera-
py, including recanalisation of an occluded vessel
(IV or IA thrombolysis) and preventing activation
of the mechanisms leading to neuronal death in the
ischaemic brain; 3) prophylaxis and treatment of
complications such as secondary haemorrhage,
space-occupying oedema, seizures, aspiration, in-
fections, decubital ulcers, deep venous thrombo-
sis and subsequent pulmonary embolism; 4) early
secondary prevention to avoid early stroke recur-
rence and 5) early rehabilitation [7].
The initial examination comprises observation
of breathing, pulmonary function and any conco-
mitant heart disease, measurement of blood pres-
sure, heart rate and arterial oxygen saturation using
infrared pulse oximetry, the drawing of blood sam-
ples for clinical chemistry, coagulation and haema-
tology studies, targeted neurological examination,
the careful taking of the medical history with the
focus on risk factors for atherosclerosis, cardiac
disease and contraindications for thrombolysis,
and determination of body weight in case throm-
bolysis, for which the dosage is weight-dependent,
is considered. The overall goal is not only to iden-
tify patients with possible stroke but also to exclu-
de stroke ‘mimics’ (conditions with stroke-like
symptoms), identify other conditions requiring
immediate intervention and determine the poten-
tial aetiology of the stroke for early secondary pre-
vention. In patients with suspected stroke cranial
computer tomography (CT) is the most important
diagnostic tool to distinguish between ischaemia
and intracranial bleeding [28, 29]. MRI may repla-
ce CT if appropriate and includes susceptibility-
-weighted sequences to identify even small ha-
emorrhages. Dynamic perfusion CT or diffusion
and perfusion-weighted MRI may be helpful in as-
sessing the risk/benefit ratio for reperfusion thera-
pies by identifying regions of salvageable brain tis-
sue. Furthermore, vascular imaging, such as CT-
-angiography, MR-angiography or ultrasonography,
may provide additional information on the paten-
Udar Mózgu 2007, tom 9, nr 2
www.um.viamedica.pl54
cy of the extracranial and intracranial arteries [30–
–33]. However, these imaging studies should not
delay the onset of thrombolytic therapy [34, 35].
Monitoring of vital and neurological function
‘General supportive care’ or ‘general stroke tre-
atment’ aims to stabilise a critically ill patient and
to control those conditions which may adversely
affect clinical outcome. Thus general supportive
care constitutes the basis upon which specific the-
rapeutic strategies may be applied [5, 7]. The mo-
nitoring of vital functions includes continuous
monitoring of heart rate and oxygen saturation,
while blood pressure may be monitored disconti-
nuously using an automatic inflatable sphygmoma-
nometer, although this should be done at least once
per hour. On-line ECG monitoring is desirable in
patients with a history of cardiac disease or arrhy-
thmia and is specifically helpful in detecting in-
termittent atrial fibrillation. Moreover, ECG elec-
trodes can be used for respiratory monitoring to
identify abnormalities during sleep [36] or to dia-
gnose a Cheynes-Stokes pattern, which occurs not
infrequently in stroke patients [37]. Assessment of
vigilance and neurological status should preferably
be performed at least every 6 hours on validated stan-
dardised scales such as the NIH stroke scale [38].
Monitoring of pulmonary function
and airway protection
The aim of monitoring respiratory function is
to maintain sufficient tissue oxygenation and to
prevent hypoxia, which could potentially worsen
brain injury in the penumbra. Administration of
> 2 l O2/min is recommended if oxygen saturation
(SaO2) is below 95%. However, routine supplemen-
tation with oxygen in every patient is not suppor-
ted by randomised clinical trials [39]. Patients with
reduced vigilance or with bulbar or pseudobulbar
paralysis have an increased risk for aspiration and
airway obstruction because of reduced oropharyn-
geal mobility and loss of the protective reflexes.
Mechanical airway protection should be conside-
red in these patients [40].
Cardiac monitoring
Atrial fibrillation is the most frequent arrhy-
thmia found in stroke patients. Furthermore, infarc-
tions of the right hemisphere, specifically those
involving the right insular cortex, are associated
with an increased risk of cardiac complications,
which can probably be explained by dysfunction
of the autonomic nervous system [41, 42]. Cardiac
monitoring is thus recommended for at least the
first 24 hours in these patients.
Monitoring of blood pressure
Arterial blood pressure is frequently elevated
in the acute phase of stroke. In many cases eleva-
ted blood pressure is a secondary response to stress,
a full bladder, nausea, pain or a reaction to eleva-
ted intracranial pressure. Elevated blood pressure
frequently declines spontaneously within a few
hours of the patient being admitted to a quiet room,
the bladder being emptied and pain relief achie-
ved [43–45]. Lowering arterial blood pressure in the
acute phase of stroke has been associated with
a poor outcome for the first time in a randomised trial
testing nimodipine against placebo [46–48]. Spe-
cifically, drops in either systolic or diastolic blood
pressure within the first 24 hours were significan-
tly related with early neurological deterioration,
larger infarct volume and, consequently, with
a poor outcome [49, 50]. Thus elevated blood pres-
sure may be tolerated in the acute phase of ischa-
emic stroke without intervention, while hypoten-
sion or a drastic reduction in blood pressure
should be avoided. However, physicians should be
aware of acute cardiac conditions, such as cardiac
failure, aortic dissection and acute coronary syn-
drome, which may require lowering of the blood
pressure. According to the guidelines of the Euro-
pean Stroke Initiative (EUSI), routine blood pres-
sure lowering is not recommended except for
extremely elevated values (> 220/120 mm Hg in ischa-
emic stroke or > 180/105 mm Hg in intracerebral ha-
emorrhage) [7]. However in patients receiving throm-
bolysis systolic blood pressure (SBP) > 180 mm Hg
should be avoided [7]. Although consensus exists
about these threshold values, they are not based on
data from randomised trials. Research activities
aiming to clarify this issue are ongoing. If blood pres-
sure lowering is necessary in the event of extreme-
ly elevated values, drugs, such as IV urapidil, which
enable SBP levels to be titrated, should be prefer-
red in order to avoid an abrupt drop in blood pres-
sure. Although the point when antihypertensive
medication should be restarted is uncertain, a tar-
get blood pressure of 180/100–105 mm Hg in pa-
tients with prior hypertension and 160–180/90–
–100 mm Hg in patients without prior hypertension
should be achieved within the first days after stroke
onset. Furthermore, physicians should avoid and
treat hypotension by administering adequate
amounts of fluid and, if required, volume expan-
ders and catecholamines (0.1–2 mg/h epinephrine).
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production of free radicals in the ischaemic penum-
bra [61, 62]. Obviously, the timing of the onset of
hyperthermia may play an important role. In a stu-
dy by Castillo et al. [63] only hyperthermia occur-
ring within the first 24 hours of stroke was an in-
dependent risk factor for poor outcome, while fe-
ver that appeared later than 24 hours after the on-
set of symptoms was not related to brain damage.
Although no beneficial effect of antipyretic treat-
ment on either febrile or afebrile acute stroke pa-
tients has yet been established, it seems reasona-
ble to lower an acutely elevated body temperature
[64–66]. EUSI recommends treating fever and its
cause when the temperature reaches 37.5 °C [7].
However, no evidence exists that patients will be-
nefit from prophylactic antibiotic treatment. In
contrast, data from the ESPIAS trial suggest that
prophylactic administration of IV levofloxacin
could be potentially harmful [67].
Monitoring fluid and electrolyte status
A balanced fluid and electrolyte status is of
great importance. It is necessary to avoid hypovo-
laemia and hypervolaemia, plasma volume contrac-
tion and raised haematocrit.
Monitoring intracranial pressure (ICP)
Routine invasive measurement of ICP is for-
tunately not necessary in the majority of patients.
However, in large middle cerebral artery infarctions
and in cerebellar infarctions, brain oedema may
occur within the first 24 to 48 hours. Elevated ICP
is therefore one of the leading causes of clinical
deterioration [68]. Impairment of consciousness
should prompt physicians to order additional CT
scans to investigate for space-occupying brain
oedema. The basic management of elevated ICP
includes head elevation of up to 30°, pain relief and
sedation, normothermia and osmotic agents. Fur-
ther escalation includes ventilatory support and
short-acting barbiturates, which may reduce ICP
significantly, although their effect is only short
lasting. To assess effective ICP reduction where
there is barbiturate treatment invasive ICP moni-
toring and EEG monitoring is recommended to de-
monstrate the burst-suppression pattern. However,
in young patients with complete middle cerebral
artery infarction, standard treatment is frequently
not effective in preventing transtentorial herniation
and the mortality rate thus rises to 80%. In these
cases decompressive surgery performed within the
first two days of stroke onset and before signs of
herniation are present has been demonstrated in
Monitoring glucose metabolism
A pooled analysis of 26 studies on the relation-
ship between hyperglycaemia and stroke outcome
revealed that in stroke patients with no history of
diabetes even moderately elevated glucose levels
were associated with a poor outcome and a three-
-fold increase in the risk of 30-day in-hospital mor-
tality in comparison with lower glucose levels [51].
Accumulation of lactate and intracellular acidosis
due to anaerobic glycolysis, lipid peroxidation and
free radical formation are possible mechanisms that
may promote neurotoxic effects in the ischaemic
penumbra region [52–54]. Furthermore, hypergly-
caemia may alter the blood–brain barrier, facilita-
ting the development of brain oedema [55]. In about
one third of patients with acute stroke, hypergly-
caemia is seen on hospital admission [56], but this
may not only reflect a history of diabetes mellitus.
It is supposed that in non-diabetic patients in par-
ticular hyperglycaemia is secondary to the stress
caused by the cerebrovascular event [51]. This
hypothesis is further supported by the observation
that hyperglycaemia is associated with more seve-
re strokes [57], leading to a greater release of stress
hormones such as cortisol or norepinephrine [51].
On the other hand, several clinical studies have
reported that persistently elevated glucose levels
independently predict expansion of the infarct
volume, neurological worsening and a poor clini-
cal outcome [51, 53, 58]. Although studies investi-
gating the effect of intervention on clinical outco-
me are lacking, there is reasonable evidence that
should prompt physicians to monitor and control
persistent hyperglycaemia in the acute phase of
stroke. The recommendations of the EUSI are that
relating hyperglycaemia to insulin should be con-
sidered when blood glucose exceeds 10 mmol/l [7].
Moreover, since hypoglycaemia could mimic stroke
symptoms, it is reasonable to correct hypoglyca-
emia by IV infusion of 10–20% glucose immedia-
tely [7].
Monitoring of body temperature
A significant, albeit mild, association between
increased body temperature in the acute phase of
stroke and poor outcome has been reported in a re-
cent meta-analysis of six studies [59]. Furthermo-
re, the Copenhagen Stroke Study revealed a 3.4-
-fold increase in the risk of one-year mortality in
stroke patients with hyperthermia compared with
normothermic patients [60]. Hypothermia may in-
crease the release of potentially cytotoxic neuro-
transmitters such as GABA and glycine, and the
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three randomised clinical trials as being the only
effective treatment option. A pooled analysis of the
DECIMAL, DESTINY and HAMLET trials revealed
an absolute risk reduction of 51% for survival with
a modified Rankin Score (mRS) £ 4, resulting in
an NNT of two [68]. Mild hypothermia is still re-
garded as experimental. Because of severe compli-
cations during re-warming, the first results from cli-
nical trials have been discouraging [69, 70].
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